EU Pharma Package hits the final stretch—but can negotiators agree?

With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

7 in-house counsel tips for partnering with AI vendors

11 November 2025 Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports.

Americas

Why AI is changing the patent rules faster than anyone can keep up

24 October 2025 A panel of experts at LSPN shared how AI is forcing companies to rethink everything from obviousness arguments to the choice between patents and trade secrets, and why the claims filed today may be invalid tomorrow.

More features

UPC appeals court hands Amgen a win in cholesterol dispute

Squires affirms USPTO’s stance on AI with revised guidance

UPC judges call for greater female advocacy at court

The clinical trial dilemma: Navigating European practice

Novartis counsel on managing patents at a $50bn company

Biotech cleared to make biosimilar of $6bn treatment after landmark ruling

Use of genAI to draft patents ‘a big concern’: CIPA’s AI chair

Still Unsettling: The uncertain landscape for discretionary denial

EU Pharma Package hits the final stretch—but can negotiators agree?

More on this story

Editor's picks

Editor's picks

More features